Access our validated preclinical in vivo pipelines, analytical method development suites, and end-to-end contract research platforms trusted by top global pharmaceutical and biopharma brands.
Navigating complex regulatory matrices, translational biology hurdles, and rigorous pharmacological efficacy validations requires a high-tier animal study supplier with seamless chemistry-to-clinic capabilities.
Over 85% of early-stage pharmacological failures stem from poorly characterized pharmacokinetics or unpredictable systemic toxicity that cannot be captured in cell culture. Sourcing certified animal studies bridges the critical bench-to-bedside gap with repeatable, physiologically authentic data packages.
With more than 14+ years of institutional history, MedGence (Yineng Pharma) operates an elite contract research infrastructure staffed by 300+ scientists and research personnel. We have successfully powered 100+ pharmaceutical manufacturers and hospitals, modernizing 83 classic TCM formulas and securing 56 hospital registrations.
Unlike disjointed testing labs, a true Contract Development & Manufacturing Partner (CRO/CDMO) unites botanical screening, chromatographic finger printing, acute/chronic toxicity, and in vivo efficacy testing directly with pilot extraction and cGMP commercial manufacturing.
Preclinical animal data is only as valuable as its legal and regulatory defensibility. When choosing an animal study supplier, international sponsors must navigate US FDA, EMA, OECD, and NMPA submission criteria without friction.
All safety assessment workflows, including LD50 determinations, repeated-dose sub-chronic toxicity, and mutagenicity assays conform to OECD Principles of GLP and US FDA 21 CFR Part 58 regulations, ensuring rapid regulatory clearance across Europe, the Americas, and Asia-Pacific.
Our barrier facilities and animal care housing follow AAALAC International accreditation criteria. Governed by an independent Institutional Animal Care and Use Committee (IACUC), protocols actively embody the 3Rs (Replacement, Reduction, Refinement) to maintain ethical integrity.
Our computerized data capture platforms enforce FDA 21 CFR Part 11 requirements with time-stamped audit trails, automated instrument logs (HPLC, mass spectrometry, clinical pathology analyzers), and strict access hierarchies to eliminate data tampering risk.
Botanical drug candidates and herbal complexes face rigorous scrutiny regarding multi-component batch variability. We provide validated chemical finger prints (HPTLC, HPLC) linked directly to the specific animal study batch for indisputable CMC-pharmacology coherence.
International biopharma sponsors and consumer health enterprises increasingly partner with China-based animal study suppliers to capitalize on unparalleled cost-efficiency, rapid study initiation, and direct integration with chemical extraction plants.
Western preclinical CRO programs often carry overwhelming facility overhead and prohibitive animal husbandry charges. Leveraging China's optimized operational scale allows life-science sponsors to complete comprehensive dose-ranging, pharmacokinetics, and chronic toxicology studies at 40%–60% of the cost of European or North American equivalents, dramatically lengthening startup cash runways.
Prolonged waitlists for rodent models, non-human primates, or transgenic lines can stall IND filing timelines. MedGence maintains high-density barrier vivariums with immediate access to disease models (STZ diabetes, ApoE atherosclerosis, DSS colitis, xenograft oncology models). Projects mobilize within days rather than months, accelerating milestones.
Located in Hunan, a historic epicenter of botanical pharmacopeias and natural materials, MedGence provides end-to-end synergy. We harvest natural actives across defined regions and seasons, evaluate chemical potency in analytical labs, test therapeutic efficacy in vivo, and immediately scale the optimal process in our CDMO pilot plant.
Procurement executives, R&D Directors, and Chief Scientific Officers prioritize distinct operational vectors when selecting an outsourced animal study supplier.
Demands GLP toxicity packages, Maximum Tolerated Dose (MTD), systemic clearance pharmacokinetics, and mechanistic biomarker telemetry to support IND applications with FDA CDER, EMA, or NMPA.
Focuses on fast, cost-effective in vivo substantiation of functional claims (metabolic wellness, gut barrier health, cognitive vitality, anti-fatigue) to satisfy FTC/EFSA substantiation requirements and elevate brand equity.
Requires rigorous skin irritation, phototoxicity, anti-inflammatory UV-erythema mitigation, and barrier repair evaluation in specialized in vivo models to substantiate clean-label performance claims without regulatory pushback.
Translates centuries-old empirical decoctions into standardized, scientifically defensible drug formats. We establish reproducible chemical fingerprints alongside targeted efficacy studies to secure commercial hospital registration dossiers.
The preclinical contract research sector is transforming rapidly. A modern animal study supplier must incorporate high-resolution bioanalytical tools and automated technologies to deliver actionable mechanistic insights.
Manual tissue slide scoring is prone to inter-observer bias. We employ automated whole-slide scanning paired with deep-learning algorithms for quantitative histology—measuring fibrotic area, immune infiltration density, and steatosis percentages with sub-micron accuracy.
Botanical medicines exert systemic effects via multi-target interactions. By integrating in vivo metabolomics, transcriptomics, and gut metagenomics, we uncover the exact biological pathways altered by herbal formulas, providing profound molecular justification for clinical trial progression.
Prior to large-scale in vivo dosing, high-throughput 3D patient-derived organoids (PDOs) and primary cell clusters are screened to pinpoint lead candidates, ensuring that only compounds with proven biological activity advance to animal validation, in alignment with 3Rs ethics.
MedGence maintains an expansive battery of phenotype-specific rodent, lagomorph, and specialized animal disease models to validate therapeutic claims across leading pharmaceutical indications.
Diet-Induced Obesity (DIO), Streptozotocin (STZ)-induced Type 1/2 diabetes, and high-fat methionine-choline deficient (MCD) NASH models. Quantitative endpoints include HOMA-IR, oral glucose tolerance tests (OGTT), liver lipid quantification, and inflammatory biomarker panels.
Subcutaneous and orthotopic murine tumor models evaluating botanical immunomodulators and novel cytotoxic molecules. Real-time tumor growth tracking, caliper measurement, flow-cytometric immune profiling (CD4+/CD8+ ratios), and survival curves.
Dextran Sulfate Sodium (DSS)-induced colitis, TNBS inflammation, and ethanol-induced acute gastric mucosal lesion models. Evaluates gut permeability (FITC-dextran assays), tight-junction protein expression (ZO-1, Claudins), and mucosal regeneration.
Scopolamine-induced amnesia, Morris water maze, open field behavioral matrices, and LPS-induced neuroinflammation models for evaluating nootropics, memory-enhancing botanicals, and neuroprotective actives.
Spontaneously Hypertensive Rats (SHR), unilateral ureteral obstruction (UUO) kidney fibrosis, and ischemia-reperfusion injury models. Monitored through non-invasive tail-cuff blood pressure, serum creatinine, BUN, and renal histopathology.
Acute toxicity (oral/dermal LD50), 14/28-day repeated-dose range-finding, 90-day sub-chronic systemic toxicity, bone marrow micronucleus test, Ames bacterial reverse mutation test, and in vivo chromosomal aberration assays.
In-depth answers addressing procurement parameters, data ownership, global compliance, and study execution timelines for life-science leaders.
We supply fully audited, GLP-compliant final study reports formatted according to ICH M4S guidelines (Nonclinical Study Reports for Common Technical Document). Every dossier incorporates study protocols, approved amendments, individual animal data sheets, bioanalytical validation reports, high-resolution digital histology scans with board-certified pathologist signatures, and the QA GLP Compliance Statement.
All client projects are conducted under legally enforceable bilateral Non-Disclosure Agreements (NDAs). MedGence operates on an entrusted CRO/CDMO basis: all testing data, synthetic processes, chromatographic fractions, and study findings belong exclusively to the client. Samples are processed under blind identification codes inside our facilities to prevent unintended compound disclosure.
Botanical extracts often suffer from seasonal and geographical potency shifts. As a dedicated natural medicine CRO, MedGence evaluates raw botanical materials by harvest season, origin, and plant part using HPLC/HPTLC fingerprinting prior to in vivo testing. We establish certified analytical standards and dosing consistency before initiating animal exposure to ensure experimental reproducibility.
Yes. Unlike standalone animal vivariums, MedGence is a comprehensive CRO/CDMO. Upon demonstrating in vivo efficacy and establishing no-observed-adverse-effect levels (NOAEL), our scientific team can formulate pilot clinical batches in our cGMP facilities and organize Phase I to Phase IV clinical trials or small-group human dietary supplement trials.
An acute oral toxicity study (LD50 / Up-and-Down procedure) is typically executed and reported within 3 to 4 weeks from protocol sign-off and compound characterization. A 28-day repeated-dose oral toxicity study with complete clinical pathology, daily health monitoring, and comprehensive tissue histopathology generally requires 8 to 12 weeks from in-life phase initiation to the audited draft report.
Absolutely. Our 300+ research scientists include veterinary surgeons and molecular pharmacologists skilled in creating tailored surgical models (e.g., bilateral ovariectomy for osteoporosis, ischemia-reperfusion), chemically-induced lesions, and gene-targeted interventions. Our study directors collaborate with your R&D team to develop, validate, and benchmark customized model protocols.
Order bespoke preclinical packages or scale existing natural active formulations with guaranteed laboratory-to-commercial manufacturing continuity.
